VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.86%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-13.64%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| 1 |
Expedia Group
EXPE
|
$932K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Gartner
IT
|
$769K |
| 4 |
Quanta Services
PWR
|
$762K |
| 5 |
Trane Technologies
TT
|
$759K |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
$778K |
| 3 |
IDEX
IEX
|
$731K |
| 4 |
Tesla
TSLA
|
$719K |
| 5 |
VICI Properties
VICI
|
$715K |
Sector Composition
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Summit Therapeutics
SMMT
$19.3B
| $91.5K | 0.06% |
35,069
-15,645
| -31% | -$40.8K |
|
|
MORF
402
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $90.5K | 0.06% |
3,133
+1,479
| +89% | +$42.7K |
|
|
VERV
403
DELISTED
Verve Therapeutics
VERV
| $90.1K | 0.06% |
6,465
+683
| +12% | +$9.52K |
|
404
Tango Therapeutics
TNGX
$772M
| $90K | 0.06% |
+9,086
| New | +$90K |
|
405
Viking Therapeutics
VKTX
$3.03B
| $89.6K | 0.06% |
4,817
+399
| +9% | +$7.43K |
|
406
Lyell Immunopharma
LYEL
$233M
| $88.9K | 0.06% |
2,292
+859
| +60% | +$33.3K |
|
407
Intellia Therapeutics
NTLA
$1.29B
| $88.6K | 0.06% |
2,906
+714
| +33% | +$21.8K |
|
408
Geron
GERN
$893M
| $88.4K | 0.06% |
41,892
+9,887
| +31% | +$20.9K |
|
409
TG Therapeutics
TGTX
$5.11B
| $87.8K | 0.06% |
5,143
+1,509
| +42% | +$25.8K |
|
410
Editas Medicine
EDIT
$248M
| $86.5K | 0.05% |
8,541
-373
| -4% | -$3.78K |
|
411
Nuvalent
NUVL
$5.83B
| $86.2K | 0.05% |
1,172
-1,124
| -49% | -$82.7K |
|
412
Prothena Corp
PRTA
$460M
| $86.2K | 0.05% |
2,373
+1,001
| +73% | +$36.4K |
|
413
Caribou Biosciences
CRBU
$174M
| $86K | 0.05% |
15,005
-6,353
| -30% | -$36.4K |
|
414
Denali Therapeutics
DNLI
$2.26B
| $85.7K | 0.05% |
3,994
+949
| +31% | +$20.4K |
|
415
Beam Therapeutics
BEAM
$2.11B
| $84.6K | 0.05% |
+3,108
| New | +$84.6K |
|
|
ALLK
416
DELISTED
Allakos
ALLK
| $80.2K | 0.05% |
29,391
+9,214
| +46% | +$25.2K |
|
417
Regenxbio
RGNX
$490M
| $79.8K | 0.05% |
4,447
-578
| -12% | -$10.4K |
|
418
Novavax
NVAX
$1.28B
| $78.1K | 0.05% |
16,271
+3,458
| +27% | +$16.6K |
|
419
BlackRock 2037 Municipal Target Term Trust
BMN
$151M
| $77.8K | 0.05% |
3,270
-1,209
| -27% | -$28.8K |
|
420
uniQure
QURE
$985M
| $77.4K | 0.05% |
11,430
+6,326
| +124% | +$42.8K |
|
421
Cassava Sciences
SAVA
$104M
| $69.2K | 0.04% |
3,075
-832
| -21% | -$18.7K |
|
422
CureVac
CVAC
$1.21B
| $67.4K | 0.04% |
16,018
+6,295
| +65% | +$26.5K |
|
423
Structure Therapeutics
GPCR
$1.27B
| $64.4K | 0.04% |
1,580
-1,614
| -51% | -$65.8K |
|
424
Copel
ELPC
$6.21B
| $44.5K | 0.03% |
+5,657
| New | +$44.5K |
|
425
Scilex Holding
SCLX
$159M
| $32.4K | 0.02% |
504
| – | – |
|